| Bioactivity | VEGFR-2-IN-43 (compound 16) is an orally active inhibitor of VEGFR2, with an IC50 of 39.91 μM. VEGFR-2-IN-43 can be used for wet age-related macular degeneration (w-AMD) disease research[1]. |
| Invitro | VEGFR-2-IN-43 (compound 16) (0-50 μM, 72 h) 对 LX-2 细胞的增殖具有弱抑制作用，对BaF3-Tel-VEGFR2 细胞的增值具有明显抑制作用[1]。VEGFR-2-IN-43 (0-10 μM, 48 h) 对 HUVEC 细胞中的 VEGFR2 磷酸化表现出浓度依赖性抑制[1]。VEGFR-2-IN-43 (1 μM, 0-120 min) 表现出显著的血浆稳定性和中等的肝微粒体稳定性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> VEGFR-2-IN-43 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | VEGFR-2-IN-43 (compound 16) (2/10 mg/kg, i.v. and p.o.) 在 ICR mice 中表现出可接受的口服生物利用度 (F = 20.2%)[1]。药代动力学分析[1]Route |
| Formula | C24H27FN4O5 |
| Molar Mass | 470.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xiu X, et al. Potential oral VEGFR2 inhibitors: Treatment of wet age-related macular degeneration. Bioorg Chem. 2024 Mar;144:107110. |